This characteristic of the NPM1mut-specific CTL product could be of advantage to counteract immune escape mechanisms developed by leukemia cells, in particular downregulation of surface HLA class I molecules, necessary for CD8+ CTL activity. The gene discussed is CD8A; the disease is leukemia.